Does Rallies show Form 4 insider transactions for HUMA?

Yes. Rallies tracks HUMA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is HUMA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HUMA. It does not provide personalized investment advice.

HUMA (Humacyte, Inc. Common Stock) Stock Analysis - Insider Trades

Humacyte, Inc. Common Stock (HUMA) is a publicly traded Healthcare sector company. As of May 20, 2026, HUMA trades at $0.86 with a market cap of $199.46M and a P/E ratio of -1.43. HUMA moved +4.64% today. Year to date, HUMA is -15.35%; over the trailing twelve months it is -62.99%. Its 52-week range spans $0.55 to $6.77. Analyst consensus is strong buy with an average price target of $2.27. Rallies surfaces HUMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading HUMA stock inside the company?

Recent HUMA insider activity includes Dougan Brady W sold 591.68K, Niklason Laura E sold 591.68K, Dougan Brady W sold 1.10M, Niklason Laura E sold 1.10M, and Dougan Brady W sold 549.36K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

HUMA Key Metrics

Key financial metrics for HUMA
Metric	Value
Price	$0.86
Market Cap	$199.46M
P/E Ratio	-1.43
EPS	$-0.59
Dividend Yield	0.00%
52-Week High	$6.77
52-Week Low	$0.55
Volume	1.64M
Avg Volume	0
Revenue (TTM)	$2.02M
Net Income	$-97.59M
Gross Margin	-475.05%

Recent HUMA Insider Trades

Dougan Brady W sold 591.68K (~$934.86K) on Aug 20, 2025.
Niklason Laura E sold 591.68K (~$934.86K) on Aug 20, 2025.
Dougan Brady W sold 1.10M (~$1.79M) on Aug 19, 2025.
Niklason Laura E sold 1.10M (~$1.79M) on Aug 19, 2025.
Dougan Brady W sold 549.36K (~$1.01M) on Aug 18, 2025.

Latest HUMA News

Humacyte Wins Surgical Implant Contract for Symvess Across 170 VA Hospitals — May 20, 2026
Symvess Sales Reach $0.5M as Humacyte Secures $1.475M Saudi Commitment — May 13, 2026
Humacyte Names Vascular Surgeon Todd Rasmussen as Chief Surgical Officer for Symvess Rollout — May 12, 2026
Humacyte Gains Exclusive Ex-U.S. Symvess Rights, Agrees Low Single-Digit Royalties — Apr 24, 2026
Humacyte Taps 25-Year Medtech Executive to Drive Symvess Launch, Dialysis BLA Push — Apr 22, 2026

HUMA Analyst Consensus

6 analysts cover HUMA: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $2.27.

Common questions about HUMA

Who is trading HUMA stock inside the company?: Recent HUMA insider activity includes Dougan Brady W sold 591.68K, Niklason Laura E sold 591.68K, Dougan Brady W sold 1.10M, Niklason Laura E sold 1.10M, and Dougan Brady W sold 549.36K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for HUMA?: Yes. Rallies tracks HUMA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is HUMA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HUMA. It does not provide personalized investment advice.